NFKB1 and colitis: For instance, COG112, a fusion peptide enhancing the bioactivity of COG133, inhibited NF‐κB signalling and reduced proinflammatory cytokine expression in murine models of colitis, indicating its potential to suppress inflammatory pathways in gastrointestinal inflammation [46].